U.S. Clinical Chemistry Analyzer Market, By Product Type (Analyzers and Reagents), Test Type (Metabolic Panel (MP), General Chemistry Test, Liver Panel, Electrolyte Panel, Renal Profile, Lipid Profile, Specialty Chemical Tests, Thyroid Fucntion Panel and Others), Modality (Benchtop, Standalone, Portable and Others), Application (Inflammatory Diseases, Diabetes, Cancer, Abuse of Drugs, Renal Failure, Cardiovascular Diseases, Nutritional Deficiency and Others), Specimen (Serum, Plasma, Urine, Cerebrospinal Fluid (CSF), Amniotic Fluid, Saliva, Blood and Others), End User (Independent Diagnostic Laboratories (Laboratories Outside Hospitals) and Hospitals), Distribution Channel (Direct Tender, Retail Sales and Others) - Industry Trends and Forecast to 2031.
U.S. Clinical Chemistry Analyzer Market Analysis and Insights
The U.S. clinical chemistry analyzer market involves various models of clinical chemistry analyzers in the U.S. such as cobas, cobas integra, and many more. The clinical chemical analyzers are primarily used to carry out tests which can indicate various health conditions such as diabetes and heart conditions among others. The analyzers can be found in independent laboratories or those in hospitals. The clinical chemistry analyzers provide accurate results with minimum turn around time and are usually semi or fully automated.
The ability of the analyzers to provide faster results help in early treatment of the indicated disorder. Major factors contributing to the growth of clinical chemistry analyzer market are technological advancement, increasing prevalence of chronic diseases and rising awareness pertaining to preventive healthcare testing. However, the high cost associated with the chemical analyzers and lack of skilled personnel act as the restraining factors for the growth of the U.S. clinical chemistry analyzer market.
Data Bridge Market Research analyzes that the U.S. clinical chemistry analyzer market is expected to reach USD 7.20 billion by 2031 from USD 5.40 billion in 2023, growing at a CAGR of 3.9% in the forecast period of 2024 to 2031.
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016–2021)
|
|
Quantitative Units
|
Revenue in USD Billion, Volume in per units, ASP
|
|
Segments Covered
|
Product Type (Analyzers, and Reagents), Test Type (Metabolic Panel (MP), General Chemistry Test, Liver Panel, Electrolyte Panel, Renal Profile, Lipid Profile, Specialty Chemical Tests, Thyroid Fucntion Panel and Others), Modality (Benchtop, Standalone, Portable and Others), Application (Inflammatory Diseases, Diabetes, Cancer, Abuse of Drugs, Renal Failure, Cardiovascular Diseases, Nutritional Deficiency and Others), Specimen (Serum, Plasma, Urine, Cerebrospinal Fluid (CSF), Amniotic Fluid, Saliva, Blood and Others), End User (Independent Diagnostic Laboratories (Laboratories Outside Hospitals) and Hospitals), Distribution Channel (Direct Tender, Retail Sales and Others)
|
|
Countries Covered
|
U.S.
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc. (Subsidiary of Danaher), Thermo Fisher Scientific Inc., Abbott, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., HORIBA, ELITech Group, Randox Laboratories Ltd., Medica Corporation, JEOL Ltd., TECO DIAGNOSTICS, FURUNO ELECTRIC CO.,LTD. and Hitachi High-Tech Corporation, among others
|
Market Definition
Clinical chemistry analyzers are automated instruments used to perform a wide range of biochemical tests on various types of samples, including blood, urine, serum, plasma, and cerebrospinal fluid. These analyzers enable healthcare professionals to measure concentrations of substances such as electrolytes, enzymes, hormones, proteins, lipids, and metabolites, providing valuable information for diagnosing and monitoring diseases, assessing organ function, and evaluating overall health status.
These analyzers can be found in various laboratories and other clinical settings such as hospitals. The applications of clinical chemistry analyzers include drugs-of-abuse testing, cardiac markers, testing for metabolic functionality, monitoring medical conditions such as diabetes among othe. The clinical chemistry analyzer market is expected to continue growing as healthcare systems worldwide prioritize preventive care, early disease detection, and personalized medicine, driving demand for advanced diagnostic technologies and solutions.
U.S. Clinical Chemistry Analyzer Market Dynamics
This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:
Driver
- Increasing Prevalence of Chronic Disease
This increase in prevalence of chronic diseases can be attributed to unhealthy lifestyles, including excess consumption of alcohol and tobacco. The above-mentioned factors also increase health risks such as obesity, high blood pressure, and cholesterol, which in turn contribute towards the unprecedented rise in the cases of chronic diseases. With increasing prevalence of diseases, the demand for early diagnosis is also increasing.
The chronic diseases such as diabetes, cardiovascular disorders, kidney diseases, and liver diseases often require regular monitoring and management. Clinical chemistry analyzers play a critical role in diagnosing these conditions, monitoring disease progression, and evaluating treatment effectiveness by measuring various biochemical parameters in bodily fluids such as blood and urine. These analyzers enable healthcare providers to perform comprehensive biochemical profiling, allowing for early detection of chronic diseases, assessment of organ function, and identification of risk factors. Early detection and proactive management of chronic diseases can help prevent complications, improve patient outcomes, and reduce healthcare costs.
Hence, the increasing prevalence of chronic diseases drives the demand for diagnostic testing, leading to the growth of the clinical chemistry analyzers market and therefore is acting as a driver for market growth.
Restraint
- High Cost Of Analyzer
The high cost of clinical chemistry analyzers can indeed be a significant barrier to their adoption and can restrain the growth of the market in several ways.
Limited Affordability: The healthcare facilities may find it challenging to afford the upfront capital investment required to purchase clinical chemistry analyzers. The high cost of acquisition can deter smaller clinics, and healthcare facilities with limited budgets from investing in these analyzers, thereby restricting their access to advanced diagnostic capabilities
Operational Expenses: In addition to the initial purchase cost, clinical chemistry analyzers often require ongoing maintenance, calibration, and consumables such as reagents and quality control materials. These operational expenses can further strain the budgets of healthcare facilities, particularly if they are already facing financial constraints. High operational costs may lead to reluctance in adopting or expanding the use of clinical chemistry analyzers.
The high cost of clinical chemistry analyzers can create barriers to entry for smaller manufacturers and startups, limiting competition in the market. As a result, there may be fewer options available to healthcare facilities, leading to less competitive pricing and slower innovation in the industry. This lack of competition can further contribute to the perception of clinical chemistry analyzers as expensive investments. Hence, the high prices of analyzers is expected to act as a restraint for the market growth.
Opportunity
- Rise in Preference for Preventive Health Check Ups
Preventive health check-ups are preventive actions performed for the initial detection of disease and safeguard against likely exposure to any disease in the future. The check-up is comprised of identification of disease and examinations of risk factors to limit loss at an early stage. Preventive health check-ups are performed with the help of various lab tests, including blood chemistry, hemoglobin, urinalysis, screening for prostate cancer, screening for ovarian cancer, ECG, lipid panel, and others.
Overall, the rising preference for preventive care creates a favorable market environment for clinical chemistry analyzers and other diagnostic technologies. As healthcare systems and consumers increasingly prioritize prevention and wellness, the demand for advanced diagnostic tools to support preventive care initiatives is expected to continue growing, and hence acting as an opportunity for the market growth.
Challenge
- Inaccurate Results of Tests
Patient safety emphasizes analyzing, reporting, and preventing medical errors, which often lead to adverse events and inappropriate clinical laboratory tests. Inappropriate clinical laboratory tests result in a greater chance of false-positive irregular outcomes, leading to serious consciousness.
Inaccurate results of tests are harmful financially and psychologically to the patients and to healthcare facilities which are decreasing authenticity, reliability and decreasing usage of clinical laboratory services due to these reason inaccurate results of tests is working as a challenge for the market.
Recent Developments
- In July 2023, F. Hoffmann-La Roche Ltd announced that it will showcase its latest product in the conference (American Association of Clinical Chemistry (AACC) Scientific Meeting). It includes featuring the newest innovations - the cobas 5800, which is a comapct, fully-automated molecular PCR-testing solution with a wide menu of assays. The product combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs. This has helped the company to make its unique position in the market
- In February 2024, Beckman Coulter, Inc. announced that it will launch new DxC 500 AU Chemistry Analyzer, an automated clinical chemistry analyzer, at Medlab Middle East in Dubai. The analyser is designed to address the complete needs of healthcare systems and has helped the company to expand its portfolio
- In July 2022, Thermo Fisher Scientific Inc. showcased its innovative diagnostic technologies, assays and a complement of solutions for researchers developing new diagnostics at 74th American Association for Clinical Chemistry Annual Scientific Meeting and Clinical Laboratory Exposition (AACC 2022). This has helped the company to display its innovative products and new technologies in the market
- In August 2023, Abbott announced that it has received FDA clearance for its advanced Alinity h-series hematology system. It will help the laboratories run complete blood counts (CBC) as a part of Abbott’s Alinity family of diagnostic products. This has helped the company to increase its product offering
U.S. Clinical Chemistry Analyzer Market Scope
The U.S. clinical chemistry analyzer market is segmented into seven notable segments based on product type, test type, modality, application, specimen, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.
Product Type
- Reagents
- Instruments
On the basis of product type, the market is segmented into reagents and instruments.
Test Type
- Metabolic Panel (MP)
- General Chemistry Test
- Lipid Profile
- Liver Panel
- Electrolyte Panel
- Renal Profile
- Specialty Chemical Tests
- Thyroid Function Panel
On the basis of test type, the market is segmented into metabolic panel (MP), general chemistry test, lipid profile, liver panel, electrolyte panel, renal profile, specialty chemical tests, and thyroid function panel.
Modality
- Benchtop
- Portable
- Standalone
- Others
On the basis of modality, the market is segmented into benchtop, portable, standalone and others.
Application
- Inflammatory Diseases
- Diabetes
- Cardiovascular Diseases
- Cancer
- Abuse of Drugs
- Renal Failure
- Nutritional Deficiency
- Others
On the basis of application, the market is segmented into inflammatory diseases, diabetes, cardiovascular diseases, cancer, abuse of drugs, renal failure, nutritional deficiency and others.
Specimen
- Serum
- Plasma
- Urine
- Cerebrospinal Fluid (CSF)
- Blood
- Amniotic Fluid
- Saliva
- Others
On the basis of specimen, the market is segmented into serum, plasma, urine, cerebrospinal fluid (CSF), blood, amniotic fluid, saliva and others.
End User
- Hospitals
- Independent Diagnostic Laboratories (Laboratories Outside Hospitals)
On the basis of end user, the market is segmented into hospitals and independent diagnostic laboratories (laboratories outside hospitals).
Distribution Channel
- Direct Tender
- Retail Sales
- Others
On the basis of distribution channel, the market is segmented into direct tender, retail sales and others.
U.S. Clinical Chemistry Analyzer Market Regional Analysis/Insights
The U.S. clinical chemistry analyzer market is categorized into seven notable segments which are based on the product type, test type, modality, application, specimen, end user and distribution channel.
U.S. clinical chemistry analyzer market is expected to grow due to presence of big major players in the market, increased development and research activities in healthcare sector. The region's early tech adoption and mature market contribute to a strong demand for advanced solutions.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and U.S. Clinical Chemistry Analyzer Market Share Analysis
The U.S. clinical chemistry analyzer market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the market.
Some of the major market players operating in the market are F. Hoffmann-La Roche Ltd, Beckman Coulter, Inc. (Subsidiary of Danaher), Thermo Fisher Scientific Inc., Abbott, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., HORIBA, ELITech Group, Randox Laboratories Ltd., Medica Corporation, JEOL Ltd., TECO DIAGNOSTICS, FURUNO ELECTRIC CO.,LTD. and Hitachi High-Tech Corporation, among others.
SKU-